Mosaic Family Wealth Partners LLC Purchases 15,979 Shares of Novo Nordisk A/S $NVO

Mosaic Family Wealth Partners LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 406.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,911 shares of the company’s stock after acquiring an additional 15,979 shares during the period. Mosaic Family Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $732,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. CIBC Bancorp USA Inc. purchased a new position in Novo Nordisk A/S during the third quarter valued at $19,519,000. Romano Brothers AND Company grew its position in shares of Novo Nordisk A/S by 704.0% in the 4th quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock worth $1,742,000 after buying an additional 29,978 shares during the period. Capital Investment Counsel LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $3,727,000. Marathon Capital Management increased its stake in shares of Novo Nordisk A/S by 43.9% in the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock worth $4,208,000 after acquiring an additional 25,230 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its position in Novo Nordisk A/S by 131.9% during the 4th quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock valued at $3,917,000 after acquiring an additional 43,793 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $0.61 during trading hours on Friday, hitting $49.49. The company’s stock had a trading volume of 6,314,361 shares, compared to its average volume of 10,696,942. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79. The company’s 50 day simple moving average is $45.57 and its two-hundred day simple moving average is $45.87. The company has a market cap of $220.96 billion, a P/E ratio of 11.62, a price-to-earnings-growth ratio of 4.46 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Finally, Wolfe Research began coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Five equities research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.